Abstract
Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 447-454 |
| Number of pages | 8 |
| Journal | Drugs of the Future |
| Volume | 36 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2011 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
5-HT4 receptor agonist treatment of chronic constipation. / Vazquez Roque, Maria I; Camilleri, Michael.
In: Drugs of the Future, Vol. 36, No. 6, 2011, p. 447-454.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - 5-HT4 receptor agonist treatment of chronic constipation
AU - Vazquez Roque, Maria I
AU - Camilleri, Michael
PY - 2011
Y1 - 2011
N2 - Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.
AB - Chronic constipation and irritable bowel syndrome (IBS) with constipation affect patient quality of life and are associated with a high healthcare expenditure. Conventional therapies for chronic constipation have limited effectiveness. New-generation, selective 5-HT4 receptor agonists are effective for chronic constipation, but none are currently approved in the U.S.; prucalopride is approved for the treatment of chronic constipation in Europe. The 5-HT4 receptor agonist velusetrag is being developed for chronic constipation and IBS with constipation; it has high selectivity and affinity for the 5-HT4 receptor. Velusetrag accelerates colonic transit in a dose-related manner, with a dose of 30 mg daily being the most effective over 9 days of treatment in healthy controls. In patients with chronic constipation, velusetrag increased spontaneous bowel movements after 4 weeks of therapy, with no serious cardiac events reported. Velusetrag has shown great promise, and further studies in chronic constipation and IBS with constipation are warranted.
UR - http://www.scopus.com/inward/record.url?scp=84952985517&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952985517&partnerID=8YFLogxK
U2 - 10.1358/dof.2011.036.06.1594078
DO - 10.1358/dof.2011.036.06.1594078
M3 - Article
VL - 36
SP - 447
EP - 454
JO - Drugs of the Future
JF - Drugs of the Future
SN - 0377-8282
IS - 6
ER -